Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Mylotarg Gemtuzumab Ozogamicin Acute Myeloid Leukemia (AML) Reimburse Complete
Myozyme Alglucosidase Pompe's disease List with clinical criteria and/or conditions Complete
Myrbetriq Mirabegron Overactive bladder List with criteria/condition Complete
Myrbetriq Mirabegron Overactive bladder Withdrawn
N/A imiquimod Gynecological cancers Withdrawn
N/A Mepolizumab Eosinophilic Granulomatosis with Polyangiitis Active
N/A dimethyl fumarate Multiple Sclerosis (MS) Active
N/A teriflunomide Multiple Sclerosis (MS) Active
N/A nab-paclitaxel Gastrointestinal cancer Reimburse with clinical criteria and/or conditions Complete
N/A blinatumomab Acute lymphoblastic leukemia, pediatrics Active